-+ 0.00%
-+ 0.00%
-+ 0.00%

Xiansheng Pharmaceutical announced on November 16 that SIM0712, an oral small molecule degrader targeting STAT6 developed independently by the company, has obtained a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis.

Zhitongcaijing·11/16/2026 23:17:34
Listen to the news
Xiansheng Pharmaceutical announced on November 16 that SIM0712, an oral small molecule degrader targeting STAT6 developed independently by the company, has obtained a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials for the treatment of atopic dermatitis.